Pfizer Inc. (NYSE:PFE) Shares Acquired by Core Wealth Partners LLC

Core Wealth Partners LLC grew its holdings in Pfizer Inc. (NYSE:PFE) by 2.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,747 shares of the biopharmaceutical company’s stock after acquiring an additional 413 shares during the period. Core Wealth Partners LLC’s holdings in Pfizer were worth $437,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. GoalVest Advisory LLC lifted its position in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Creekmur Asset Management LLC purchased a new stake in Pfizer in the fourth quarter valued at $32,000. Trivant Custom Portfolio Group LLC lifted its position in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the last quarter. VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners acquired a new position in Pfizer in the fourth quarter valued at $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE traded down $0.13 on Thursday, hitting $27.70. The company’s stock had a trading volume of 15,180,087 shares, compared to its average volume of 29,961,926. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The company has a market capitalization of $156.96 billion, a price-to-earnings ratio of -461.59, a price-to-earnings-growth ratio of 1.09 and a beta of 0.69. The stock has a 50 day moving average of $27.99 and a 200-day moving average of $27.71. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $37.80.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.23 earnings per share. As a group, research analysts predict that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.06%. The ex-dividend date of this dividend is Thursday, July 25th. Pfizer’s payout ratio is -2,799.53%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on PFE. Morgan Stanley lifted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Wednesday, June 26th. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Nine investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $35.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.